Discover Our Group:

Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992. 

Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.

Discover More about Global Responsibility

From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet

Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice. 

Discover More about Global Partnering

Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.

Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.

Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.

Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material. 

Menarini Blog

Follow Us

We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.

Our Job Portal

Find out about our current vacancies at Berlin-Chemie directly on our career portal.

News

Slider News

2024 - 10 - 22

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque congue, sapien vitae finibus porta, sapien enim congue est, sed facilisis nunc ex at nisl. Nam sit amet consectetur ipsum. Aliquam tincidunt dolor et leo tincidunt, ac finibus nibh egestas. Ut sed lacus sit amet eros pulvinar viverra. Nullam nisl turpis, venenatis ut nunc vitae, pulvinar interdum lorem. Sed vel libero at urna efficitur malesuada. Sed a tincidunt tellus. Etiam maximus scelerisque lectus placerat hendrerit. Quisque faucibus, sapien et varius suscipit, ante tellus semper ex, id lacinia velit lectus ut felis. In hac habitasse platea dictumst. Suspendisse sed accumsan nunc, vitae sodales justo. Praesent faucibus quis sapien non pellentesque. Duis commodo sit amet lectus sed tristique. Cras nibh ligula, faucibus quis turpis ac, congue congue diam.